证券代码：300261 证券简称：雅本化学 公告编号：2026-007 雅本化学股份有限公司 关于召开2026年第一次临时股东会通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据雅本化学股份有限公司（以下简称"公司"）第六届董事会第八次（临 时）会议的决定，公司将于 2026 年 2 月 12 日召开公司 2026 年第一次临时股东 会，现将有关事项通知如下： 一、本次会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会召集人：公司董事会 3、会议召开的合法、合规性：经公司第六届董事会第八次（临时）会议审 议通过，决定召开 2026 年第一次临时股东会，本次会议的召集、召开符合《中 华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、 部门规章、规范性文件及《公司章程》的有关规定。 4、会议召开的日期、时间 现场会议时间：2026 年 2 月 12 日（星期四）下午 14:30 网络投票时间：2026 年 2 月 12 日 通过深圳证券 ...

雅本化学股份有限公司 第六届董事会第八次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司")第六届董事会第八次（临时）会议 于 2026 年 1 月 26 日下午 15:00 以现场结合通讯方式召开，会议通知已于 2026 年 1 月 20 日以邮件方式送达全体董事。本次会议应出席董事 9 名，实际出席会议董事 9 名。会议由公司董事长兼总经理蔡彤先生主持，部分高级管理人员列席了会议。本 次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 一、审议通过了《关于公司及子公司2026年度向银行申请综合授信的议案》 经审议，为了满足经营发展的需要，公司及子公司 2026 年度拟向银行申请不超 过人民币 360,000 万元的综合授信额度，在此额度内由公司及子公司根据实际资金 需求进行借贷。为便于公司及子公司 2026 年度向银行申请授信额度工作顺利进行， 现提请公司董事会授权董事长、总经理蔡彤先生全权处理上述申请授信额 ...

证券日报网讯1月23日，雅本化学（300261）在互动平台回答投资者提问时表示，公司取得肟菌酯合成 专利，有助于优化产品的生产工艺，推动实现提质增效的经营目标。但专利的商业转化存在不确定性， 暂无法确认对该产品的产能和成本的影响，请注意风险。针对农药"一品一证"行业新规及2026年病虫害 发生趋势，公司农化业务依托全产业链布局，积极响应市场需求，在创新中间体和创新原药实现突破， 致力于加强产能储备与供应链保障，以期提升公司经营业绩。 ...

（文章来源：证券日报） 证券日报网讯 1月23日，雅本化学在互动平台回答投资者提问时表示，本公司全资子公司江苏建农控股 的甘肃兰沃科技有限公司近期取得四唑虫酰胺原药登记（登记证号：PD20252901），系国内本土企业 取得的该原药产品首项登记。需说明的是，甘肃兰沃为该产品授权定制加工企业，相关产品将按合作约 定组织生产供应（CDMO），不涉及自产自销及导致市场格局变动的相关情形。产品具体产量、价格涉 及合作商业信息，暂不便披露。未来，公司将持续聚焦工艺升级与产能优化，在合规前提下保证供应链 稳定，以响应客户需求，助力农业绿色发展。 ...

证券日报网讯 1月23日，雅本化学在互动平台回答投资者提问时表示，目前公司医药业务聚焦创新医药 中间体、原料药CDMO服务，暂未涉及创新药自主研发与商业化布局。 （文章来源：证券日报） ...

Group 1 - The agricultural chemical sector increased by 1.05% on January 23, with Zhongqi Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Notable stock performances included Zhongqi Co., Ltd. with a closing price of 6.98, up 10.97%, and Zhongnong United with a closing price of 60.61, up 10.03% [1] Group 2 - The agricultural chemical sector experienced a net outflow of 258 million yuan from institutional investors, while retail investors saw a net inflow of 254 million yuan [2] - The top stocks by net inflow from retail investors included Chuanfa Longmang with a net inflow of 1.32 billion yuan and Chengxing Co., Ltd. with a net inflow of 8.44 million yuan [3] - The overall trading volume for the agricultural chemical sector was significant, with stocks like Chengxing Co., Ltd. and Dongfang Iron Tower recording high transaction amounts of 12.32 billion yuan and 11.16 billion yuan respectively [1][2]

Core Viewpoint - Yabao Chemical (300261) is progressing with its C93 workshop at the Lanzhou base, which is not yet operational, while Lanwo Technology has achieved stable production and delivery of pesticide intermediates [1] Group 1 - The C93 workshop at the Lanzhou base is advancing in an orderly manner and has not yet commenced operations [1] - Lanwo Technology has successfully achieved stable mass production and delivery of pesticide intermediates [1] - The chairman's remarks focus on the long-term development trends and outlook of the company, without constituting any performance forecasts or commitments [1]

Core Viewpoint - The collaboration model between Yabao Chemical and Heng Rui Medicine is based on the CDMO (Contract Development and Manufacturing Organization) model, which encompasses all stages from preclinical to commercial production [1]. Group 1 - Yabao Chemical engages in a CDMO partnership with Heng Rui Medicine [1]. - The collaboration covers various phases of drug development, including preclinical and commercial production [1].

证券日报网讯1月13日，雅本化学（300261）在互动平台回答投资者提问时表示，截至2026年1月9日， 公司股东总数为52305户。 ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining global attention in the health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant regulatory advancements expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2][19]. Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with significant milestones achieved in countries like Japan, Canada, the US, and Australia [17][18]. - In China, NMN has been approved as a new cosmetic ingredient and is on the path to becoming a recognized health food, with the National Market Supervision Administration listing it for health food approval in April 2025 [17][18]. Market Demand - The aging population in China is driving the "silver economy," with projections indicating that the elderly population will grow from 320 million to 390 million between 2025 and 2030, creating a substantial market for anti-aging products [19]. - The younger generation, particularly those born in the 1990s, is increasingly aware of anti-aging needs, further boosting market demand for NMN products [19]. Technological Advancements - Innovations in synthesis, quality testing, and delivery methods are driving the NMN industry forward, with full enzyme methods significantly enhancing production efficiency and reducing costs [21][22]. - The transition from chemical synthesis to full enzyme methods is leading to higher purity and environmental sustainability in NMN production [10][12]. Application Areas - NMN is primarily used in health supplements and cosmetics, with the health supplement market accounting for nearly 90% of its applications, including anti-aging and immune support products [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues for the industry [24][28]. Market Size and Growth - The NMN market in China is projected to exceed 3 billion yuan by 2025, driven by increasing regulatory clarity and expanding applications in various sectors [28][32]. - The market has been growing steadily since 2020, with significant penetration into health supplements and cosmetics [28][32]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60% to 70% of market share [35][34]. - Brand private channels are also showing strong performance, capturing about 30% of the market share [35]. Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. - Achieving this certification could significantly reshape the market landscape for NMN products in China [37]. Future Prospects - The NMN industry is poised for growth, with regulatory breakthroughs expected to enhance market opportunities, particularly in the cosmetics sector [51]. - The potential for NMN in pet nutrition, medical health, and agricultural technology is also being explored, indicating a broadening of its application scope [53][56][58].